Strategic Asset Sale The company sold assets to Merit Medical Systems for $105M in July 2024, indicating a potential shift in product ownership and licensing opportunities for complementary GERD technology or ongoing service partnerships.

Leadership Transition Recent leadership changes include a new CEO in December 2022 and an ongoing shift in key executive roles, suggesting opportunities to engage in strategic alliances, funding, or channel development discussions aligned with a refreshed growth plan.

SalesCapability Historical high-performing sales leadership with a track record of growing revenue to over $30M annually before the asset sale; potential for re-engagement or partnership with a rebuilt or reoriented commercial organization.

GERD Focus Core technology targets the GERD treatment market with the TIF procedure and EsophyX platform, indicating demand for endoscopy-ready devices, accessories, training, and post-market support for surgeons and gastroenterologists.

Education and Outreach Initiatives such as GERD Gourmet and awareness campaigns demonstrate appetite for clinician education, patient engagement, and brand-building programs that can be expanded through partnerships, digital content, and training collaborations.